U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H42N8O3.3H2O
Molecular Weight 616.7521
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PINOMETOSTAT TRIHYDRATE

SMILES

O.O.O.CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3N)[C@@H]4C[C@H](CCC5=NC6=C(N5)C=CC(=C6)C(C)(C)C)C4

InChI

InChIKey=UQPFPXXVGVCSCX-MIFIOKNMSA-N
InChI=1S/C30H42N8O3.3H2O/c1-16(2)37(13-22-25(39)26(40)29(41-22)38-15-34-24-27(31)32-14-33-28(24)38)19-10-17(11-19)6-9-23-35-20-8-7-18(30(3,4)5)12-21(20)36-23;;;/h7-8,12,14-17,19,22,25-26,29,39-40H,6,9-11,13H2,1-5H3,(H,35,36)(H2,31,32,33);3*1H2/t17-,19+,22-,25-,26-,29-;;;/m1.../s1

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C30H42N8O3
Molecular Weight 562.7063
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26385168

Pinometostat, also known as EPZ-5676, is a small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. Upon intravenous administration, EPZ-5676 specifically blocks the activity of the histone lysine-methyltransferase DOT1L, thereby inhibiting the methylation of nucleosomal histone H3 on lysine 79 (H3K79) that is bound to the mixed lineage leukemia (MLL) fusion protein which targets genes and blocks the expression of leukemogenic genes. Epizyme is developing pinometostat, a small molecule inhibitor of DOT1L, for the treatment of patients with MLL-r, a genetically defined acute leukemia. Epizyme is conducting a phase 1 clinical trial in pediatric patients. Epizyme is evaluating preclinical combinations of pinometostat with other anti-cancer agents in MLL-r leukemia. Pinometostat is being developed in collaboration with Celgene. Epizyme retains all U.S. rights to pinometostat and has granted Celgene an exclusive license to pinometostat outside of the U.S.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 80.0 pM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
438
Unknown

Approved Use

Unknown
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27160567
unknown, unknown
 PINOMETOSTAT plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
90 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 90 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 90 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
DLT: cardiac failure...
Other AEs: Ejection fraction decreased, Cardiorespiratory arrest...
Dose limiting toxicities:
cardiac failure (grade 4, 1 pt)
Other AEs:
Ejection fraction decreased (grade 3-4, 2%)
Cardiorespiratory arrest (grade 3-4, 2%)
Hypophosphatemia (grade 3-4, 2%)
Cardiac failure congestive (grade 3-4, 4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
AEs

AEs

AESignificanceDosePopulation
Cardiorespiratory arrest grade 3-4, 2%
90 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 90 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 90 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
Ejection fraction decreased grade 3-4, 2%
90 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 90 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 90 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
Hypophosphatemia grade 3-4, 2%
90 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 90 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 90 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
Cardiac failure congestive grade 3-4, 4%
90 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 90 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 90 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
cardiac failure grade 4, 1 pt
DLT
90 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 90 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 90 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/29724899/
PubMed

PubMed

TitleDatePubMed
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
2013-08-08
The pathogenesis of mixed-lineage leukemia.
2012
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
2011-07-12
Patents

Patents

20120142625
3
20140051654
3

Sample Use Guides

In Vivo Use Guide
28-day continuous IV infusion of each 28-day cycle
Route of Administration: Intravenous
In Vitro Use Guide
Pinometostat reduces H3K79 dimethylation with a cellular IC50 of 2.6 nM in MV4-11 cells. Pinometostat treatment results in concentration- and time-dependent reduction of H3K79 methylation without effect on the methylation status of other histone sites, which leads to inhibition of key MLL target genes and selective, apoptotic cell killing in MLL-rearranged leukemia cells. Pinometostat inhibits proliferation of MLL-AF4 rearranged cell line MV4-11 with an IC50 of 9 nM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:43:12 GMT 2025
Edited
by admin
on Mon Mar 31 21:43:12 GMT 2025
Record UNII
RHP89XVN70
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PINOMETOSTAT TRIHYDRATE
Common Name English
ADENOSINE, 5'-DEOXY-5'-((CIS-3-(2-(6-(1,1-DIMETHYLETHYL)-1H-BENZIMIDAZOL-2-YL)ETHYL)CYCLOBUTYL)(1-METHYLETHYL)AMINO)-, HYDRATE (1:3)
Preferred Name English
Code System Code Type Description
CAS
1643929-61-6
Created by admin on Mon Mar 31 21:43:12 GMT 2025 , Edited by admin on Mon Mar 31 21:43:12 GMT 2025
NON-SPECIFIC STOICHIOMETRY
FDA UNII
RHP89XVN70
Created by admin on Mon Mar 31 21:43:12 GMT 2025 , Edited by admin on Mon Mar 31 21:43:12 GMT 2025
PRIMARY
PUBCHEM
91617704
Created by admin on Mon Mar 31 21:43:12 GMT 2025 , Edited by admin on Mon Mar 31 21:43:12 GMT 2025
PRIMARY
SMS_ID
300000006060
Created by admin on Mon Mar 31 21:43:12 GMT 2025 , Edited by admin on Mon Mar 31 21:43:12 GMT 2025
PRIMARY
CAS
1628338-78-2
Created by admin on Mon Mar 31 21:43:12 GMT 2025 , Edited by admin on Mon Mar 31 21:43:12 GMT 2025
PRIMARY
Related Record Type Details
Structure of PINOMETOSTAT
ANHYDROUS->SOLVATE
Related Record Type Details
Structure of PINOMETOSTAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966